Sa1861 Post-Ablation Safety Margin of Radiofrequency Ablation of Hepatocellular Carcinoma: Precise Assessment with a Three Dimensionalreconstruction Technique

Yanyan Zhang,Zhengpeng Peng,Weifeng Liu,Ming Kuang

DOI: https://doi.org/10.1016/s0016-5085(15)33513-7

IF: 29.4

2015-01-01

Gastroenterology

Abstract:the angiogenesis-independent antitumor effects of apatinib in EBDC.Methods: Three EBDC cell lines FRH, TFK-1and EGI were examined for basal expression of VEGF, VEGFR1, and VEGFR2 by western blotting (WB).The cells were treated with recombinant human VEGF (rhVEGF), and VEGFR phosphorylation was examined by WB, and cell proliferation was evaluated by BrdU incorpation assay.Cells were then treated with 0, 60, or 120 nM of apatinib for 24 hour, and were assayed for VEGFR signaling and cell proliferation.Finally, FRH cells were inoculated into nude mice for further evaluation for apatinib treatment efficacy in vivo.Results: All three EBDC cell lines expressed VEGF and phosphorylated (p) VEGF receptor 1 (pVEGFR1) and 2 (pVEGFR2).By protein fractionalization, we found that VEGFR1 and VEGFR2 were both present on membrane of these three cells.The rhVEGF promoted phosphorylation of VEGFR1 and VEGFR2 at 30 min (FRH and EGI) or 15 min after treatment.The rhVEGF increased cell proliferation (+16.8%,+13.4% and +20.5% for FRH, TFK and EGI respectively) after 24 hr of treatment, which was prevented by preincubation with VEGFR1 or VEGFR2 neutralizing antibody.Apatinib treatment inhibited the phosphorylation of VEGFR1 and VEGFR2 and cell proliferation in all three cell lines in a dose-dependent fashion.Finally, the apatinib-treated FRH xenograft tumors displayed a substantial delayed growth after one week-treatment.The averages of final tumor volumes were significantly different between the vehicle and apatinib-treated groups after 4 weeks of treatment (P<0.05).Conclusion: VEGF directly activated VEGF receptors on EBDC cells and promoted cancer cell proliferation; apatinib inhibited VEGF signaling and suppressed cell proliferation in vitro and delayed xenograft tumor growth in vivo.These findings support a potential role for apatinib in the treatment of extrahepatic bile duct cancers.